tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-019tumors-1413Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL NOTESЛечение пациента с диссеминированной герминогенной опухолью яичка на фоне терминальной хронической болезни почек, требующей проведения гемодиализаTreatment of a patient with disseminated testicular germ cell tumor associated with terminal chronic kidney disease requiring hemodialysishttps://orcid.org/0000-0002-6750-5201АбляметоваА. С.AblyametovaA. S.

Абляметова Авашерфе Сапуетовна

115478 Москва, Каширское шоссе, 23; 117997 Москва, ул. Островитянова, 1

Ablyametova Avasherfe Sapuetovna

23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997

avasherfe99@mail.ruhttps://orcid.org/0009-0004-4632-3195ЗориноваА. В.ZorinovaA. V.

Зоринова Алина Владимировна

115478 Москва, Каширское шоссе, 23; 117997 Москва, ул. Островитянова, 1

Zorinova Alina Vladimirovna

23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997

https://orcid.org/0000-0003-4481-4164ЛетучихА. Н.LetuchikhA. N.

Летучих Ангелина Николаевна

115478 Москва, Каширское шоссе, 23; 117997 Москва, ул. Островитянова, 1

Letuchikh Angelina Nikolaevna

23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997

https://orcid.org/0000-0002-6666-549XИсраелянЭ. Р.IsraelyanE. R.

Исраелян Эдгар Рудикович

115478 Москва, Каширское шоссе, 23

Israelyan Edgar Rudikovich

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0002-0635-9343ЦареваА. С.TsarevaA. S.

Царева Анастасия Сергеевна

115478 Москва, Каширское шоссе, 23

Tsareva Anastasiya Sergeevna

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0003-4443-9974РумянцевА. А.RumyantsevA. A.

Румянцев Алексей Александрович

115478 Москва, Каширское шоссе, 23

Rumyantsev Aleksei Aleksandrovich

23 Kashirskoe Shosse, Moscow 115478

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Federation2024181220241437985Copyright © Абляметова А.С., Зоринова А.В., Летучих А.Н., Исраелян Э.Р., Царева А.С., Румянцев А.А., 20242024Абляметова А.С., Зоринова А.В., Летучих А.Н., Исраелян Э.Р., Царева А.С., Румянцев А.А.Ablyametova A.S., Zorinova A.V., Letuchikh A.N., Israelyan E.R., Tsareva A.S., Rumyantsev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1413

Среди онкологических пациентов существует когорта больных с терминальной хронической болезнью почек (ХБП), развившейся вследствие различных причин и требующей назначения гемодиализа. Проведение противоопухолевого лекарственного лечения при данном сопутствующем заболевании возможно, однако требует выбора наиболее оптимальных модифицированных режимов химиотерапии (ХТ) с целью достижения максимальной эффективности и минимизации токсичности лечения. В данном клиническом случае мы описываем наш лечебный подход для пациента, находящегося на гемодиализе, с метастатической несеминомной герминогенной опухолью (ГО) яичка неблагоприятного прогноза по классификации International Germ Cell Cancer Collaborative Group (IGCCCG). Нами был проведен анализ литературных данных, отражающих применение различных лекарственных препаратов и режимов ХТ, используемых для лечения ГО у пациентов с ХБП.

There is a cohort of cancer patients with terminal chronic kidney disease (CKD) due to various causes and requiring hemodialysis. Antitumor drug therapy in this concomitant disease is possible, but requires selection of the most optimal modified chemotherapy (CT) regimens to maximize efficacy and minimize treatment toxicity. In this case report we describe our therapeutic approach for a patient on hemodialysis with a metastatic non-seminomatous germ cell tumor (GCT) of the testis of poor prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. We analyzed the literature datareflecting the use of different drugs and CT regimens used for the treatment of GCT in patients with CKD.

герминогенная опухольхимиотерапияхроническая болезнь почекгемодиализgerm cell tumorchemotherapychronic kidney diseasehemodialysisСтатья подготовлена без спонсорской поддержкиThe article was prepared without sponsorshipReferencesAlifrangis С., Sharma A., Chowdhury S., et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. EurJ Cancer 2022;164:105-113. https://doi.Org/10.1016/j.ejca.2020.08.031Alifrangis С., Sharma A., Chowdhury S., et al. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. EurJ Cancer 2022;164:105-113. https://doi.Org/10.1016/j.ejca.2020.08.031Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;ll(4):598-606. https://doi.Org/10.1200/JCO.1993.ll.4.598Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;ll(4):598-606. https://doi.Org/10.1200/JCO.1993.ll.4.598Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52. https://doi.org/10.1200/JC0.1997.15.5.1844Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52. https://doi.org/10.1200/JC0.1997.15.5.1844Feldman D.R., Bosl G.J., Sheinfeld J., et al. Medical treatment of advanced testicular cancer. JAMA 2008;299(6):672-84. https://doi.Org/10.1001/jama.299.6.672. PMID: 18270356Feldman D.R., Bosl G.J., Sheinfeld J., et al. Medical treatment of advanced testicular cancer. JAMA 2008;299(6):672-84. https://doi.Org/10.1001/jama.299.6.672. PMID: 18270356Hanna N.H., Einhorn L.H. Testicular cancer-discoveries and updates. N Engl J Med 2014;371(21):2005-16. https://doi.org/10.1056/NEJMral407550. Erratum in: N EnglJ Med 2014;371(24):2342. PMID: 25409373Hanna N.H., Einhorn L.H. Testicular cancer-discoveries and updates. N Engl J Med 2014;371(21):2005-16. https://doi.org/10.1056/NEJMral407550. Erratum in: N EnglJ Med 2014;371(24):2342. PMID: 25409373Feldman D.R. State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book 2018;38:319-323. https://doi.org/10.1200/EDBK_201139Feldman D.R. State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book 2018;38:319-323. https://doi.org/10.1200/EDBK_201139Gillessen S., Sauve N., Collette L., et al. International Germ Cell Cancer Classification Update Consortium. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol 2021;39(14):1563—1574. https://doi.org/10.1200/JCO.20.03296. Erratum in: J Clin Oncol 2022;40(20):2283. PMID: 33822655Gillessen S., Sauve N., Collette L., et al. International Germ Cell Cancer Classification Update Consortium. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol 2021;39(14):1563—1574. https://doi.org/10.1200/JCO.20.03296. Erratum in: J Clin Oncol 2022;40(20):2283. PMID: 33822655Fizazi K., Pagliaro L., Laplanche A., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumors (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014;15:1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5Fizazi K., Pagliaro L., Laplanche A., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumors (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014;15:1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5Janus N., Launay-Vacher V., Yhyss A., et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013;24(2):501—507. https://doi.org/10.1093/annonc/mds344Janus N., Launay-Vacher V., Yhyss A., et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 2013;24(2):501—507. https://doi.org/10.1093/annonc/mds344Bokemeyer C., Kohrmann O., Tischler J., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7(10):1015—21. https://doi.org/10.1093/oxfordjournals.annonc.a010493Bokemeyer C., Kohrmann O., Tischler J., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7(10):1015—21. https://doi.org/10.1093/oxfordjournals.annonc.a010493Moore K.J., Snow S., Wood L.A. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Curr Oncol 2022;29(3):1808-1812. https://doi.org/10.3390/curroncol29030148Moore K.J., Snow S., Wood L.A. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Curr Oncol 2022;29(3):1808-1812. https://doi.org/10.3390/curroncol29030148Gorodetsky R., Vexler A., Bar-Khaim Y., et al. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995;17(2):203—6. https://doi.org/10.1097/00007691-199504000-00018Gorodetsky R., Vexler A., Bar-Khaim Y., et al. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995;17(2):203—6. https://doi.org/10.1097/00007691-199504000-00018Ikeda K., Terashima M., Kawamura H., et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998;28(3):168-75. https://doi.Org/10.1093/jjco/28.3.168Ikeda K., Terashima M., Kawamura H., et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998;28(3):168-75. https://doi.Org/10.1093/jjco/28.3.168Janus N., Thariat J., Boulanger H., et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010;21(7):1395—1403. https://doi.org/10.1093/annonc/mdp598Janus N., Thariat J., Boulanger H., et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010;21(7):1395—1403. https://doi.org/10.1093/annonc/mdp598Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-vCrooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-vLatcha S., Maki R.G., Schwartz G.K., et al. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009;2009:575629. https://doi.org/10.1155/2009/575629Latcha S., Maki R.G., Schwartz G.K., et al. Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. Sarcoma 2009;2009:575629. https://doi.org/10.1155/2009/575629Hirakawa H., Nakashima Ch., Nakamura T., et al. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep 2017;ll(l):43 https://doi.org/10.1186/sl3256-017-1213-7Hirakawa H., Nakashima Ch., Nakamura T., et al. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep 2017;ll(l):43 https://doi.org/10.1186/sl3256-017-1213-7Froehner M., Passauer J., Schuler U., et al. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis. J Clin Oncol 2007;25(10):1282-4. https://doi.org/10.1200/JCO.2006.09.9549Froehner M., Passauer J., Schuler U., et al. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis. J Clin Oncol 2007;25(10):1282-4. https://doi.org/10.1200/JCO.2006.09.9549Tryakin A., Fedyanin M., Bulanov A., et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.J Cancer Res Clin Oncol 2018;144(9):1817-1823. https://doi.org/10.1007/s00432-018-2695-4Tryakin A., Fedyanin M., Bulanov A., et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.J Cancer Res Clin Oncol 2018;144(9):1817-1823. https://doi.org/10.1007/s00432-018-2695-4Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N EnglJ Med 1987;316(23):1435-40. https://doi.org/10.1056/NEJM198706043162302Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N EnglJ Med 1987;316(23):1435-40. https://doi.org/10.1056/NEJM198706043162302Crooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-vCrooke S.T., Luft F., Broughton A., et al. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977;39(4):1430—4. https://doi.org/10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-vR de Wit., Stoter G., Sleijfer D.T., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78(6):828-32. https://doi.org/10.1038/bjc,1998.587R de Wit., Stoter G., Sleijfer D.T., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998;78(6):828-32. https://doi.org/10.1038/bjc,1998.587Feldman D., Hu J., Srinivas S., et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate-or poor-risk germ cell tumors (GCT). J Clin Oncol 2018;36(15 suppl):4508-4508. https://doi.org/10.1200/JCO.2018.36.15_suppl.4508Feldman D., Hu J., Srinivas S., et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate-or poor-risk germ cell tumors (GCT). J Clin Oncol 2018;36(15 suppl):4508-4508. https://doi.org/10.1200/JCO.2018.36.15_suppl.4508Collette L., Sylvester R.J., Stenning S.P., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839-46. https://doi.org/10.1093/jnci/91.10.839Collette L., Sylvester R.J., Stenning S.P., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839-46. https://doi.org/10.1093/jnci/91.10.839Клинические рекомендации. Герминогенные опухоли у мужчин, 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/584_lКлинические рекомендации. Герминогенные опухоли у мужчин, 2020. Доступно по: https://cr.minzdrav.gov.ru/recomend/584_l

The authors declare that there are no conflicts of interest present.